SCT in Ph Positive Acute Lymphoblastic Leukemia

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

441 participants

Study Classification

OBSERVATIONAL

Study Start Date

2016-10-26

Study Completion Date

2018-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study includes a registry-based, nationwide analysis to describe the clinical outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) who underwent an allogeneic hematopoietic stem cell transplantation (HSCT) after a Tyrosine Kinase Inhibitors (TKI)-based treatment.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effect of Prophylactic TKI Therapy Post-transplants on Ph+ ALL Undergoing Allo-HSCT With MRD Positive Pre-transplants

NCT03624530

Philadelphia Chromosome Positive Acute Lymphocytic Leukemia Tyrosine Kinase Inhibitor Minimal Residual Disease +1 more

UNKNOWN PHASE2/PHASE3

A Study of TKI Maintenance Therapy Following Allo-HSCT in Newly Diagnosed Ph+ Adult ALL

NCT05024357

Precursor Cell Lymphoblastic Leukemia-Lymphoma Philadelphia-Positive Acute Lymphoblastic Leukemia ALL, Adult

UNKNOWN NA

GITMO AML/MDS-Relapse Registry Study

NCT06790680

Acute Myeloid Leukaemia Myelodysplastic Syndrome

COMPLETED

Irradiation-based Myeloablative Conditioning Followed by Treg/Tcon Immunotherapy in HSCT

NCT03977103

Acute Myeloid Leukemia Acute Lymphoid Leukemia Myeloproliferative Disorders +3 more

UNKNOWN PHASE2

TKI Therapy Based on Molecular Monitoring in Allogeneic-HSCT Recipients With Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia

NCT01883219

Philadelphia Chromosome Positive Acute Lymphocytic Leukemia Stem Cell Transplantation Minimal Residual Disease

UNKNOWN PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This was a retrospective nationwide analysis based on registry data collected by GITMO. Inclusion criteria were: 1) diagnosis of Ph+ ALL; age ≥18 years at transplant; 2) patients receiving first allogeneic HSCT from any donor (HLA-identical sibling donor (MSD), unrelated donor (UD) or alternative donor (haploidentical or cord blood) between 2005 and 2016 in a GITMO center; 3) TKI-based treatment prior to HSCT; 4) patients with available pre-transplant MRD status, as well as complete clinical data and outcome. Data were extracted from the GITMO Registry (PROMISE Registry).

The endpoints of the study were: OS, progression-free survival (PFS), cumulative incidence of relapse (CIR), non-relapse mortality (NRM), cumulative incidence of extensive chronic graft versus host disease (cGVHD), rate of minimal residual disease (MRD) negativity and the rate of complete cytologic remission (CR) before and after transplant.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Philadelphia Positive Acute Lymphoblastic Leukemia SCT

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

OTHER

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Hematopoietic Stem Cell Transplantation

Hematopoietic Stem Cell Transplantation in Acute Leukemia Ph positive

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosis of Ph+ ALL; age ≥18 years at transplant.
* Patients receiving first allogeneic HSCT from any donor (HLA-identical sibling donor (MSD), unrelated donor (UD) or alternative donor (haploidentical or cord blood) between 2005 and 2016 in a GITMO center.
* TKI-based treatment prior to HSCT.
* Patients with available pre-transplant MRD status, as well as complete clinical data and outcome.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No